Novel Treatment Strategies for Cancer
癌症新治疗策略
基本信息
- 批准号:10193053
- 负责人:
- 金额:$ 28.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAntibioticsArachidonic AcidsAreaBioenergeticsBiogenesisBiologicalBiological MarkersBypassCell DeathCell SurvivalCell modelCellsChromophobe Renal Cell CarcinomaClinicalClinical TrialsCombined Modality TherapyCommunitiesConsumptionConventional (Clear Cell) Renal Cell CarcinomaDiagnosisDrug KineticsFDA approvedFatty AcidsFutureGenetic TranscriptionGlucoseGlycolysisGoalsGrowthHalf-LifeHourHydrolysisKnowledgeLaboratoriesLeadLinoleic AcidsLipid PeroxidationLipidsLysophospholipidsMalignant Epithelial CellMalignant NeoplasmsMarshalMetabolicMetabolic PathwayMetabolic stressMetabolismMitochondriaMitochondrial ProteinsModelingMolecular TargetMusNonesterified Fatty AcidsNutrient DepletionOncologyOxidative PhosphorylationPapillaryPapillary CarcinomaPatient-Focused OutcomesPatientsPeroxidasesPhospholipidsPolyunsaturated Fatty AcidsProductionProto-Oncogene Proteins c-aktRegimenRenal carcinomaReportingResearchRespirationSamplingSignal PathwaySignal TransductionSubgroupSurvival RateSystemTestingTherapeuticTherapeutic EffectTranslatingUnsaturated Fatty AcidsWorkbasecancer cellcancer therapyclinically relevantcytotoxicitydriver mutationdrug testingeffective therapyfatty acid oxidationimprovedimproved outcomein vivoinhibitor/antagonistmouse modelnon-genomicnovelnovel drug combinationpharmacodynamic biomarkerphospholipid-hydroperoxide glutathione peroxidaseresponsesynergismtigecyclinetranscriptional reprogrammingtranscriptomicstreatment strategytumortumor growthtumor metabolism
项目摘要
PROJECT SUMMARY: Novel treatment strategies for cancer
The urgent need to develop effective treatments for non-clear cell renal cell carcinomas (NCCRCC) is underscored by consistently poor overall survival, despite decades of clinical trials. This is because there are no biologically rational treatments for NCCRCC, compared to conventional clear cell renal cell carcinomas. Accordingly, the lack of therapies for NCCRCC is a critical clinical unmet need.
We addressed this need by developing a novel JAK and AKT inhibitor combination treatment that blocked the growth of NCCRCC cancer cells invitro and in mouse models. Importantly, we discovered a non-genomic early adaptive survival signal following JAK-AKT inhibition therapy characterized by a “lipid reprogrammed” transcriptional state. This non-genomic metabolic adaptation resulted in phospholipid hydrolysis to mobilize lysophospholipids and free fatty acids to sustain fatty acid oxidation and oxidative phosphorylation. Our objective is to definitely establish the mechanistic and functional basis for this observed effect. This leads us to hypothesize that the induction of metabolic catastrophe is essential to inducing cytotoxicity. We will test this hypothesis as follows: In Aim 1, we will explore how mitochondrial biogenesis and dynamics converge to increase respiration in the setting of metabolic stress. Next, in Aim 2, we will elucidate how lysophospholipids and fatty acids are marshalled to maintain cancer cell survival despite nutrient depletion. Importantly, in both aims we will seek to discover molecular targets that can potentially lead to even more potent therapeutic combinations.
The extension of this research to the broader scientific and clinical community will be significant because this work will establish the framework for co-targeting of signaling and metabolic pathways to improve and extend the lives of patients with NCCRCC.
项目总结:癌症的新治疗策略
尽管进行了数十年的临床试验,但非透明细胞肾细胞癌(NCCRCC)的总生存率一直很低,这突出了开发有效治疗方法的迫切需要。这是因为与传统的透明细胞肾细胞癌相比,NCRCC没有生物学上合理的治疗方法。因此,NCRCC缺乏治疗是一个关键的临床未满足的需求。
我们通过开发一种新的JAK和AKT抑制剂组合治疗来解决这一需求,该治疗可以在体外和小鼠模型中阻断NCCRCC癌细胞的生长。重要的是,我们发现了JAK-AKT抑制治疗后的非基因组早期适应性生存信号,其特征在于“脂质重编程”转录状态。这种非基因组代谢适应导致磷脂水解以动员溶血磷脂和游离脂肪酸来维持脂肪酸氧化和氧化磷酸化。我们的目标是明确建立这种观察到的效果的机制和功能基础。这使我们假设,诱导代谢灾难是必不可少的诱导细胞毒性。我们将测试这一假设如下:在目标1中,我们将探讨如何线粒体生物合成和动力学收敛,以增加呼吸代谢应激的设置。接下来,在目标2中,我们将阐明溶血磷脂和脂肪酸如何在营养耗尽的情况下维持癌细胞存活。重要的是,在这两个目标中,我们将寻求发现可能导致更有效的治疗组合的分子靶点。
将这项研究扩展到更广泛的科学和临床社区将具有重要意义,因为这项工作将建立共同靶向信号传导和代谢途径的框架,以改善和延长NCCRCC患者的生命。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
George Victor Thomas其他文献
George Victor Thomas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('George Victor Thomas', 18)}}的其他基金
Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma
开发非透明细胞肾细胞癌的新型多疗法
- 批准号:
10555185 - 财政年份:2021
- 资助金额:
$ 28.8万 - 项目类别:
Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma
开发非透明细胞肾细胞癌的新型多疗法
- 批准号:
10308505 - 财政年份:2021
- 资助金额:
$ 28.8万 - 项目类别:
Biospecimen Acquisition, Processing and Classification Unit
生物样本采集、处理和分类装置
- 批准号:
10005914 - 财政年份:2018
- 资助金额:
$ 28.8万 - 项目类别:
Biospecimen Acquisition, Processing and Classification Unit
生物样本采集、处理和分类装置
- 批准号:
10471934 - 财政年份:2018
- 资助金额:
$ 28.8万 - 项目类别:
Biospecimen Acquisition, Processing and Classification Unit
生物样本采集、处理和分类装置
- 批准号:
10246895 - 财政年份:2018
- 资助金额:
$ 28.8万 - 项目类别:
相似海外基金
Can antibiotics disrupt biogeochemical nitrogen cycling in the coastal ocean?
抗生素会破坏沿海海洋的生物地球化学氮循环吗?
- 批准号:
2902098 - 财政年份:2024
- 资助金额:
$ 28.8万 - 项目类别:
Studentship
Metallo-Peptides: Arming Cyclic Peptide Antibiotics with New Weapons to Combat Antimicrobial Resistance
金属肽:用新武器武装环肽抗生素以对抗抗菌素耐药性
- 批准号:
EP/Z533026/1 - 财政年份:2024
- 资助金额:
$ 28.8万 - 项目类别:
Research Grant
The role of RNA repair in bacterial responses to translation-inhibiting antibiotics
RNA修复在细菌对翻译抑制抗生素的反应中的作用
- 批准号:
BB/Y004035/1 - 财政年份:2024
- 资助金额:
$ 28.8万 - 项目类别:
Research Grant
Towards the sustainable discovery and development of new antibiotics
迈向新抗生素的可持续发现和开发
- 批准号:
FT230100468 - 财政年份:2024
- 资助金额:
$ 28.8万 - 项目类别:
ARC Future Fellowships
DYNBIOTICS - Understanding the dynamics of antibiotics transport in individual bacteria
DYNBIOTICS - 了解抗生素在单个细菌中转运的动态
- 批准号:
EP/Y023528/1 - 财政年份:2024
- 资助金额:
$ 28.8万 - 项目类别:
Research Grant
Engineering Streptomyces bacteria for the sustainable manufacture of antibiotics
工程化链霉菌用于抗生素的可持续生产
- 批准号:
BB/Y007611/1 - 财政年份:2024
- 资助金额:
$ 28.8万 - 项目类别:
Research Grant
The disulfide bond as a chemical tool in cyclic peptide antibiotics: engineering disulfide polymyxins and murepavadin
二硫键作为环肽抗生素的化学工具:工程化二硫多粘菌素和 murepavadin
- 批准号:
MR/Y033809/1 - 财政年份:2024
- 资助金额:
$ 28.8万 - 项目类别:
Research Grant
Role of phenotypic heterogeneity in mycobacterial persistence to antibiotics: Prospects for more effective treatment regimens
表型异质性在分枝杆菌对抗生素持久性中的作用:更有效治疗方案的前景
- 批准号:
494853 - 财政年份:2023
- 资助金额:
$ 28.8万 - 项目类别:
Operating Grants
Imbalance between cell biomass production and envelope biosynthesis underpins the bactericidal activity of cell wall -targeting antibiotics
细胞生物量产生和包膜生物合成之间的不平衡是细胞壁靶向抗生素杀菌活性的基础
- 批准号:
2884862 - 财政年份:2023
- 资助金额:
$ 28.8万 - 项目类别:
Studentship
Narrow spectrum antibiotics for the prevention and treatment of soft-rot plant disease
防治植物软腐病的窄谱抗生素
- 批准号:
2904356 - 财政年份:2023
- 资助金额:
$ 28.8万 - 项目类别:
Studentship